Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Swiss National Bank

Swiss National Bank grew its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 1.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 126,600 shares of the biopharmaceutical company’s stock after buying an additional 1,300 shares during the period. Swiss National Bank owned 0.17% of Xenon Pharmaceuticals worth $4,963,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Loomis Sayles & Co. L P grew its stake in Xenon Pharmaceuticals by 7.1% during the 3rd quarter. Loomis Sayles & Co. L P now owns 707,222 shares of the biopharmaceutical company’s stock valued at $27,843,000 after acquiring an additional 46,964 shares in the last quarter. Vestal Point Capital LP grew its position in shares of Xenon Pharmaceuticals by 57.1% in the third quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company’s stock valued at $32,480,000 after purchasing an additional 300,000 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Xenon Pharmaceuticals by 1,263.2% in the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock valued at $38,456,000 after purchasing an additional 905,129 shares in the last quarter. Barclays PLC lifted its position in Xenon Pharmaceuticals by 1,275.5% during the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $590,000 after buying an additional 13,903 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in Xenon Pharmaceuticals during the third quarter worth approximately $4,132,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on XENE. Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 target price for the company. William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Finally, Royal Bank of Canada restated an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $57.38.

Xenon Pharmaceuticals Price Performance

Shares of XENE opened at $36.45 on Tuesday. The firm has a 50-day simple moving average of $38.11 and a two-hundred day simple moving average of $39.85. The stock has a market cap of $2.79 billion, a PE ratio of -12.93 and a beta of 1.26. Xenon Pharmaceuticals Inc. has a 1-year low of $33.27 and a 1-year high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.05. As a group, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Insider Activity at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $40.20, for a total value of $903,213.60. Following the completion of the transaction, the chief executive officer now owns 31,302 shares in the company, valued at approximately $1,258,340.40. The trade was a 41.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.52% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.